HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paula Poikonen-Saksela Selected Research

Docetaxel (Taxotere)

1/2022Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
6/2017Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paula Poikonen-Saksela Research Topics

Disease

5Breast Neoplasms (Breast Cancer)
01/2022 - 06/2017
3Neoplasms (Cancer)
01/2022 - 06/2017
1Leukopenia
07/2020
1Triple Negative Breast Neoplasms
06/2017

Drug/Important Bio-Agent (IBA)

3Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 06/2017
3Epirubicin (Ellence)FDA LinkGeneric
01/2022 - 06/2017
2Docetaxel (Taxotere)FDA Link
01/2022 - 06/2017
2Capecitabine (Xeloda)FDA Link
01/2022 - 06/2017
2Estrogen ReceptorsIBA
01/2022 - 06/2017
1taxaneIBA
01/2022
1AnthracyclinesIBA
01/2022
1TabletsIBA
05/2021
1human ERBB2 proteinIBA
06/2017
1Progesterone Receptors (Progesterone Receptor)IBA
06/2017
1Hormones (Hormone)IBA
06/2017
1SteroidsIBA
06/2017

Therapy/Procedure

3Adjuvant Chemotherapy
01/2022 - 07/2020
3Therapeutics
01/2022 - 01/2021
2Drug Therapy (Chemotherapy)
01/2022 - 07/2020